Hoth Therapeutics

183 articles with Hoth Therapeutics

• Hoth Therapeutics Announces Collaboration with First Active Clinical Site for its Phase 2 Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

  3/8/2023

  Hoth Therapeutics, Inc. today announced the activation of Washington University School of Medicine in St. Louis as the first clinical site in the CLEER-001 Phase 2a clinical trial of HT-001.

• Hoth Therapeutics Announces Increased Positive Results of its Alzheimer's Therapeutic HT-ALZ

  2/8/2023

  Hoth Therapeutics, Inc.  today announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer's disease mouse model (aged APP/PS1+/- mice), supporting the therapeutic cognitive potential of HT-ALZ after chronic oral dosing of 20mg/kg and 40mg/kg of HT-ALZ.

• Hoth Therapeutics Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

  1/25/2023

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical  company, today announced that it has selected 3 of its clinical sites for its Phase 2a clinical trial for the treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy.

• Hoth Therapeutics Announces FDA Acceptance of IND Application for HT-001 for the Treatment of Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

  12/29/2022

  Hoth Therapeutics, Inc. announced that the U.S. Food and Drug Administration has accepted an Investigational New Drug application for the company's HT-001 therapeutic for the treatment for rash and skin disorders associated with epidermal growth factor receptor inhibitor therapy.

• Hoth Therapeutics Announces Submission of Investigational New Drug Application for HT-001

  12/1/2022

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on December 1, 2022.

• Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements - November 09, 2022

  11/9/2022

  Hoth Therapeutics, Inc. announced that it received written notice from the NASDAQ Stock Market LLC on November 9, 2022, informing the Company that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550 for continued listing on the NASDAQ Capital Market.

• HOTH THERAPEUTICS REPORTS POSITIVE BIOLEXA PHASE 1B CLINICAL TRIAL RESULTS IN MILD TO MODERATE ATOPIC DERMATITIS

  10/31/2022

  Hoth Therapeutics  today announced positive data for BioLexa, its investigational therapeutic in a Phase 1b clinical trial in adult patients with mild-to-moderate atopic dermatitis.

• Hoth Therapeutics Announces a 1:25 Reverse Stock Split Effective Pre-Market Opening on October 26, 2022

  10/24/2022

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will effect a 1-for-25 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on October 26, 2022.

• Hoth Therapeutics Announces Partnership with Altasciences for Manufacturing HT-TBI for Traumatic Brain Injury and Stroke

  9/20/2022

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has signed an agreement with Altasciences, a fully integrated early phase CRO/CDMO, to develop and manufacture the HT-TBI drug product formulation.

• Hoth Therapeutics mRNA Frame-Shifting Therapeutic, HT-004, Shows Potential to Reduce Lung Inflammation in Asthma and Allergy Disorders

  9/6/2022

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced development updates for its novel asthma and allergy maintenance therapeutic, HT-004.

• Hoth Therapeutics Announces Pipeline Presentation at the 2022 Sidoti Investor Conference

  8/12/2022

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today announced the company will be presenting at the Sidoti Investor Conference taking place on August 17-18, 2022.

• Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer's Disease Mouse Model

  7/12/2022

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer's disease mouse model (aged APP/PS1+/- mice), supporting the therapeutic cognitive potential of HT-ALZ after chronic oral dosing.

• Hoth Therapeutics Granted 180 Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

  6/29/2022

  Hoth Therapeutics, Inc. announced that the Company received confirmation from the Listing Qualification Department of The NASDAQ Capital Market notifying the Company that Nasdaq has granted the Company an additional 180-day compliance period, or until December 26, 2022, to regain compliance with Nasdaq's minimum $1.00 closing bid price per share requirement.

• Hoth Therapeutics Announces HREC Approval in Australia for the Next Phase of its Trial of BioLexa for Patients with Atopic Dermatitis

  6/21/2022

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has received approval by the Bellberry Human Research Ethics Committee (HREC) in Australia to initiate the next phase of its BioLexa trial for patients suffering with Atopic Dermatitis.

• Hoth Announces Adjournment of Annual Meeting of Shareholders Until June 23, 2022

  6/15/2022

  Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, announced that its Annual Meeting of Shareholders scheduled for and convened on June 15, 2022 was adjourned until 12:00 p.m. Eastern Time on June 23, 2022 to allow additional time to solicit proxies and obtain a quorum for the Annual Meeting.

• Hoth Therapeutics Announces Extension of Washington University Alzheimer's Mouse Model Study with Alzheimer's Therapeutic HT-ALZ

  6/9/2022

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company, today announced that it has entered into an extension of its Sponsored Research Agreement with Washington University in St. Louis.

• 

  Clinical Catch-Up: Pfizer's Paxlovid Gaff, a Win for Medicago-GSK's Vaccine

  5/9/2022

  Pfizer's Paxlovid racks up a rare trial miss, Medicago and GSK publish positive data for their plant-based particle vaccine and Rhythm Pharmaceuticals touts strong potential in Bardet-Biedl Syndrome.

• Hoth Therapeutics Announces Preliminary Efficacy Findings From Phase 1b Clinical Trial with Mild to Moderate Atopic Dermatitis Patient Cohort

  5/3/2022

  Hoth Therapeutics, Inc. today announced the preliminary findings from Hoth's randomized, double-blind, placebo-controlled Phase 1b study investigating the safety and efficacy of BioLexa Lotion in patients with mild to moderate atopic dermatitis.

• Hoth Therapeutics Announces New Pipeline Asset, HT-TBI for Stroke and Traumatic Brain Injury

  4/19/2022

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the company is adding a new asset to its pipeline portfolio, HT-TBI, which is based on scientific research performed by Hoth.

• Hoth Therapeutics, Inc. Announces Closing of $7.0 Million Underwritten Public Offering Priced At-The-Market

  4/14/2022

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 8,235,294 shares of common stock (the "Common Stock") at a public offering price of $0.85 per share.